Komori
Ono Pharmaceutical (4528) · RiskQuantification of the financial impact under climate change scenarios

Risk of production disruptions caused by natural disasters, fires and other events

First written in FY2016. 2 of 8 entries say "Mitigated", first in FY2021. Latest entry: FY2026.

8entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2016 – FY2020MitigatedFY2021 – FY20252016: 120162017: 020172018: 120182019: 020192020: 120202021: 120212022: 020222023: 120232024: 120242025: 120252026: 12026
Same theme, other companies

The whole theme swung hardest in 2018: 32 of 131 companies on the "Worse" side.

4 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 187 companies compared. The sentences above are computed from all 187.Comparing 200 of the theme's 501 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026Quantification of the financial impact under climate change scenariosAnnual report

    「In particular, the physical risks under the 4°C scenario, namely natural disasters such as torrential rain, typhoons and flooding, are viewed as risks that could affect the stable supply of high-quality pharmaceuticals.」

    Climate change scenario analysis quantified the impact of operational disruptions caused by natural disasters under the 4°C scenario at approximately ¥10 billion, and the Group stated that it would continue BCP measures including securing inventory and using multiple locations.
  2. FY2025AdvancedAnnual report

    「The BCM Committee, which is responsible for business continuity management (BCM), is working to formulate all-hazards business continuity plans capable of responding not only to natural disasters and major accidents but also to a wide range of incidents. In addition, the Group is developing global crisis response and business continuity plans covering its overseas subsidiaries.」

    In addition to multiple domestic production and logistics sites and seismic isolation and power outage measures, the Group has expanded its response to all-hazards BCPs and global crisis response covering overseas subsidiaries.
  3. FY2024AdvancedAnnual report

    「In addition, with a view to direct sales in Europe and the United States, the Group is developing global crisis response and business continuity plans covering its overseas subsidiaries.」

    The response to natural disasters and accidents has been expanded from multiple domestic locations, seismic isolation systems and employee safety confirmation measures to global crisis response and BCPs covering overseas subsidiaries.
  4. FY2023MitigatedAnnual report

    「In addition, seismic isolation systems have been installed at the head office, Tokyo Building, Minase Research Institute and Yamaguchi Plant to mitigate earthquake risks. The Group is also developing its internal response structure for large-scale disasters, including a framework enabling response from 2 locations, Osaka and Tokyo, and the introduction of an “employee safety confirmation system” to confirm employees’ safety as quickly as possible.」

    Measures against natural disasters have been expanded to include 2 production sites, multiple logistics sites, seismic isolation systems at key locations, dual-location response capabilities, an employee safety confirmation system and disaster training.
  5. FY2021MitigatedAnnual report

    「The Group mitigates risks to ensure a stable supply of its products by securing 2 production sites, the Fujiyama Plant in Shizuoka Prefecture and the Yamaguchi Plant in Yamaguchi Prefecture, as well as multiple logistics sites in Japan. At key locations, including the head office, Tokyo Building, each plant and each research laboratory, it has installed disaster-prevention equipment such as emergency power supply systems and dual power-receiving lines to address power outages.」

    Specific redundancy and response measures are described for the risk of supply disruptions caused by natural disasters or accidents, including 2 production sites, multiple logistics sites, emergency power supplies and dual power-receiving lines.
  6. FY2020Expansion of the risks covered and strengthened response measuresAnnual report

    「The Group implements disaster preparedness measures for production plants and key business locations in response to natural disasters such as earthquakes and flooding associated with climate change, including water risks. It also develops business continuity plans (BCPs) and addresses climate change risks based on the recommendations of the TCFD.」

    Climate change and flooding, including water risks, have been added to the existing natural disaster and fire risks, with responses based on BCPs and the TCFD recommendations described.
  7. FY2018RestatedAnnual report

    「If production is disrupted or delayed by natural disasters, fires or other events, resulting in interruptions to product supply, the Group’s operating results and financial position may be materially affected.」

    The risk of production disruptions caused by natural disasters or fires and delays in product supply has been reiterated.
  8. FY2016First statedAnnual report

    「If production is disrupted or delayed by natural disasters, fires or other events, resulting in interruptions to product supply, the Group’s operating results and financial position may be materially affected.」

    Production stoppages or delays caused by natural disasters or fires, and interruptions to product supply, are identified as business risks.
Moved together

"Expansion of the development pipeline and continued launches of new drugs" moved the same way as this thread, in the same document, in 4 of its 8 moves.

444433★123456
  1. ★This thread
  2. 1Expansion of the development pipeline and continued launches of new drugs4×
  3. 2Global business expansion and international launches4×
  4. 3Drug Discovery Collaborations with Universities, Research Institutions and Biotech Ventures4×
  5. 4Holding Shares to Maintain and Strengthen Business Relationships4×
  6. 5Strengthening Oversight Functions through the Board of Directors, Board of Corporate Auditors and Outside Officers3×
  7. 6Long-term enhancement of corporate value and alignment of interests with shareholders3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Ono Pharmaceutical's next results are scheduled for 2026-10-29. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of production disruptions caused by natural disasters, fires and other events | ONO PHARMACEUTICAL CO.,LTD. (4528) | Komori